Piper Jaffray analyst Charles Duncan highlights Cara Therapeutics (CARA) as his top pick going into 2016. The analyst likens the company's position to Neurocrine's (NBIX) last year, which he points out gained 150% at the end of 2014 to present. Cara has "notable value creation" potential from two Phase III read-outs of candidates with a "well-vetted mechanism of action in large-market indications," Duncan tells investors in a New Year's Eve research note. The analyst expects Cara's peak sales to reach four times its current market capitalization. He recommends buying the stock ahead of the Phase III readouts and keeps an Overweight rating on the stock with a $34 price target. Duncan expects the company to begin a pivotal trial of IV'845 in uremic pruritus in early 2016, with data being announced likely in Q4. Cara closed yesterday down 33c to $15.79 with a market cap of just below $440M.